Efficacy and Safety of First-line ART With BIC/FTC/TAF Introduced at the First Clinical Visit

Efficacy and Safety of First-line Antiretroviral Therapy (ART) With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Introduced at the First Clinical Visit: a Real-life Retrospective Single Arm Single Center Study

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recommended first-line antiretroviral regimen. Croatia has a centralized care for people living with HIV (PLWH) and all persons are seen and treated in a single center, preferably in a same-day initiation model whenever suitable. This retrospective cohort study evaluated antiretroviral therapy (ART) naïve PLWH who initiated BIC/FTC/TAF, in a same-day model. The goal of the study is to assess safety and efficacy of this model by collecting information from the electronic database of the Croatian HIV Reference Centre.

Inclusion Criteria:

• HIV seropositivity confirmed by a fourth generation test
• the subject had not previously taken ART
• ART was started within 24 hours of the first examination

Exclusion Criteria:

• persons under 18 years of age
• people who are pregnant, breastfeeding or planning to become pregnant
• unacceptable interaction with a drug that the subject is already taking